Genmab AS (NAS:GMAB)
$ 23.12 -0.02 (-0.09%) Market Cap: 14.68 Bil Enterprise Value: 12.55 Bil PE Ratio: 19.09 PB Ratio: 3.24 GF Score: 88/100

Q3 2022 Genmab A/S Earnings Call Transcript

Nov 09, 2022 / 05:00PM GMT
Release Date Price: $41.28 (+3.12%)
Operator

Hello, and welcome to the Genmab Q3 2022 Conference Call. As a reminder, this conference call is being recorded. (Operator Instructions) During this telephone conference, you may be presented with forward-looking statements that include words such as beliefs, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects. Genmab is not under any obligation to update statements regarding the future nor to confirm such statements in relation to actual results, unless it is required by law. Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy. I would now like to hand the conference over to your first speaker today, Jan van Winkel. Please go ahead.

Jan G.J. van de Winkel;S;Co;Founder
Genmab A;President & CEO

/-- -

Hello,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot